Sandoparin (certoparin sodium) / Viatris, Aspen Pharma - LARVOL DELTA

Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Lung Cancer Receiving Chemotherapy (ASH 2023) - "The prophylactic doses of bemiparin, certoparin, dalteparin, nadroparin, semuloparin and tinzaparin, intermediate dose of enoxaparin and prophylactic dose of rivaroxaban and apixaban were used in the studies. In our subgroup meta-analysis of POTP with DOACs, there was no statistically significant difference in reduction of VTE in LC patients with Khorana Score ≥2. Hence, the selection of appropriate patients who are high risk for VTE is crucial and further studies are required to define high risk subsets of LC patients receiving chemotherapy who may benefit from POTP."

Retrospective data • Cardiovascular • Lung Cancer • Oncology • Solid Tumor • Venous Thromboembolism

Comparative efficacy of certoparin, enoxaparin, and combined thromboprophylaxis on thromboembolic events after glioblastoma resection: a prospective observational study. (PubMed, Sci Rep) - "GBM patients treated with enoxaparin alone have a significantly higher risk for TE compared to treatment with certoparin or the combination of enoxaparin with IPS. Additionally, the duration of surgery, patient age and comorbidities significantly influence the risk of postoperative TE."

Clinical • Journal • Observational data • Retrospective data • Brain Cancer • Cardiovascular • Coronary Artery Disease • Diabetes • Glioblastoma • Heart Failure • Hematological Disorders • Metabolic Disorders • Oncology • Pulmonary Embolism • Respiratory Diseases • Solid Tumor

Influence of anticoagulant concomitant medication on wound healing: Analysis of a multicentre cohort of 212 patients with a uniform wound model. (PubMed, Br J Clin Pharmacol) - "Enoxaparin and nadroparin may enhance wound healing, whereas phenprocoumon, acetylsalicylic acid, and certain low-molecular-weight heparins (certoparin, tinzaparin, dalteparin, bemiparin) appear to delay wound healing. Anticoagulant monotherapy with enoxaparin or nadroparin should be considered postoperatively when feasible."

Journal

The efficacy and safety of low-molecular-weight heparins for venous thromboembolism prophylaxis in abdominal or pelvic cancer surgery: A systematic review and network meta-analysis of randomized controlled trials. (PubMed, Thromb Res) - "LMWHs are efficacious options for thromboprophylaxis in patients undergoing abdominal or pelvic cancer surgery, without increasing the risk of major bleeding or all-cause death. However, no significant differences were observed in efficacy and safety among different types of LMWHs used in this context."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Oncology • Thrombocytopenia • Venous Thromboembolism

PRIMARY AMBULATORY THROMBOPROPHYLAXIS (PATP) IN PATIENTS WITH LUNG CANCER UNDERGOING SYSTEMIC THERAPY: UPDATED ANALYSIS OF RANDOMIZED STUDIES (EHA 2024) - "5,526 patients with LC from five RCTs and subgroups of another six RCTs were eligible. Bemiparin, certoparin,dalteparin, nadroparin, semuloparin, tinzaparin, enoxaparin, rivaroxaban and apixaban were used. The durationof the anticoagulation ranged from 3 to 6 months."

Clinical • Cardiovascular • Hematological Disorders • Lung Cancer • Oncology • Solid Tumor • Venous Thromboembolism

Prophylactic Anticoagulation With Intermediate-Dose Certoparin in Vascular-Risk Pregnancies-The PACER-VARP Registry. (PubMed, Clin Appl Thromb Hemost) - "One case of pre-eclampsia necessitating obstetric intervention occurred. Prophylactic anticoagulation with intermediate-dose certoparin throughout pregnancies at increased venous vascular risk was safe and effective."

Journal • Cardiovascular • Gynecology • Hematological Disorders • Obstetrics • Venous Thromboembolism • PROS1

Sudden exercise dyspnea in a young woman - an interdisciplinary case in the emergency room (PubMed, Dtsch Med Wochenschr) - " OHSS is primarily a gynaecological condition, but physicians may encounter it with exercise dyspnea or abdominal pain as presenting symptoms. Symptoms can be treated well at an early stage, and severe courses can usually be prevented. In this case, clinical history and sonography could disprove the initially suspected diagnosis of pulmonary embolism."

Journal • Cardiovascular • Pain • Pulmonary Embolism • Respiratory Diseases

Low molecular weight heparins and their clinical applications. (PubMed, Prog Mol Biol Transl Sci) - "Eight chemically distinct and officially approved LMWHs are Bemiparin, Certoparin, Dalteparin, Enoxaparin, Nadroparin, Parnaparin, Reviparin, and Tinzaparin. In particular, we will provide an update on the chemical characteristics and clinical use of different branded LMWHs. In addition, the potential clinical applications of LMWHs in other therapeutic area will also be discussed."

Clinical • Journal

Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Locally Advanced or Metastatic Lung Cancer Receiving Chemotherapy (ASH 2019) - "The prophylactic doses of bemiparin, certoparin, dalteparin, nadroparin, semuloparin and tinzaparin, intermediate dose of enoxaparin and prophylactic dose of rivaroxaban were used in the studies. Our analysis showed that the relative risk reduction is 46% with a NNT of 28 to prevent one VTE without increasing MB events in ambulatory patients with locally advanced or metastatic LC. Selection of appropriate patients who are high risk for VTE is crucial and further studies are required to define high risk subsets of LC patients receiving chemotherapy who may benefit from PATP."

Retrospective data

Activity of maleimide functionalized unfractionated and low molecular weight heparins (GTH 2019) - "Three different LMWH (enoxaparin, certoparin and tinzaparin) as well as two UFH (Merck, ratiopharm) were functionalized with N-(2-aminoethyl)maleimide TFA to a final degree of one maleimide group/heparin molecule. However, the maleimide moiety triggered an immediate loss of heparin activity upon its addition to whole blood and an increased clot formation.[Heparin molecule size dependent clot formation of heparinized whole blood under coagulant conditions]The functionalization of heparins with a reactive maleimide moiety offers a potential strategy for surface immobilization of both UFH and LMWH. The approach does not affect the heparins potential to inhibit the coagulation factors FIIa and FXa, but an immediate loss of activity was detected for the functionalized compounds in whole blood."